Kim Popovits
Chairman of the Board, Chief Executive Officer and President, Genomic Health, Inc.

Therapeutic Implications of the Use of ODX in ER Positive, Node Positive Patients with Early Breast Cancer

Therapeutic Implications of the Use of Colon ODX in Stage II and III Disease

Norman Wolmark, MD
Chairman and Principal Investigator of the National Surgical Adjuvant Breast and Bowel Project (NSABP), Professor and Chairman of Human Oncology, Drexel University School of Medicine Philadelphia, Pennsylvania

DCIS: Making the Punishment Fit the Crime

William C. Wood, MD, FACS, FRCS (Hon) Eng, FRCS Glasg.
Distinguished Joseph Brown Whitehead Professor of Surgery, Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Joint Professor of Global Health, Hubert Department of Global Health, Rollins School of Public Health

Refined Risk Assessment Leads to Refined Treatment for Prostate Cancer

Peter R. Carroll, MD, MPH
Professor and Chair, Ken and Donna Derr - Chevron Distinguished Professor Department of Urology, Associate Dean, Director of Clinical Services and Strategic Planning UCSF - Helen Diller Comprehensive Cancer Center University of California, San Francisco